Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 2026 Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the…
WELL Health and HEALWELL AI Launch WELLTRUST to Empower Patients and Accelerate AI Powered Ethical Patient Identification for Clinical Research WELL Health Technologies Corp. a technology-enabled healthcare company operating outpatient…
Shufti Sets a New Benchmark for VideoIdent in the DACH Market Shufti, a global identity verification and compliance technology provider announced the expansion of its VideoIdent solution across Germany, Austria, and Switzerland…
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine Merck known as MSD outside of the U.S. and Canada, and Mayo Clinic,…
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer The European Medicines Agency (EMA) has validated the Type II Variation…
Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM) Affinia Therapeutics an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class…
Icon Group Deploys ChartCheck Adaptive Across Australia as Radformation Secures USFDA 510(k) Clearance Radformation, a leading provider of intelligent automation solutions for radiation oncology, and Icon Group (Icon), a leading global integrated…
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Spruce Biosciences, Inc. a late-stage biopharmaceutical company focused on…
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline KalVista Pharmaceuticals, Inc. today announced that the newly published…
Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases Korsana Biosciences, Inc. a biotechnology company discovering and developing novel therapies to…
GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments GenSight Biologics a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases…
Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced a major, peer-reviewed publication demonstrating the…